SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., traded on Nasdaq under ticker BCYP, is a clinical-stage biopharmaceutical company that entered public markets through a business combination with Big Cypress Acquisition Corp, a special purpose acquisition company that completed its initial public offering in 2020. The SPAC operated in the healthcare and life sciences sector prior to its merger with SAB Biotherapeutics, a developer of human polyclonal antibody therapeutics produced via a genetically engineered cattle platform targeting infectious diseases and other serious conditions. The company filed an 8-K with the SEC on June 18, 2026, reflecting continued regulatory reporting activity as a post-combination publicly traded entity. Sign up at SpacDesk for full filing history, deal analytics, and real-time data on BCYP and hundreds of other SPAC transactions.